[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3153511T3 - Pochodna 2-acyloaminotiazolu do stosowania do profilaktyki lub leczenia chorób pęcherza moczowego/dróg moczowych - Google Patents

Pochodna 2-acyloaminotiazolu do stosowania do profilaktyki lub leczenia chorób pęcherza moczowego/dróg moczowych

Info

Publication number
PL3153511T3
PL3153511T3 PL15803484T PL15803484T PL3153511T3 PL 3153511 T3 PL3153511 T3 PL 3153511T3 PL 15803484 T PL15803484 T PL 15803484T PL 15803484 T PL15803484 T PL 15803484T PL 3153511 T3 PL3153511 T3 PL 3153511T3
Authority
PL
Poland
Prior art keywords
bladder
prevention
treatment
urinary tract
tract diseases
Prior art date
Application number
PL15803484T
Other languages
English (en)
Inventor
Taisuke Takahashi
Takanori Koike
Kenji Negoro
Hiroaki Tanaka
Jun Maeda
Kazuhiro Yokoyama
Hajime Takamatsu
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL3153511T3 publication Critical patent/PL3153511T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL15803484T 2014-06-06 2015-06-05 Pochodna 2-acyloaminotiazolu do stosowania do profilaktyki lub leczenia chorób pęcherza moczowego/dróg moczowych PL3153511T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014118046 2014-06-06
PCT/JP2015/066321 WO2015186821A1 (ja) 2014-06-06 2015-06-05 ２－アシルアミノチアゾール誘導体またはその塩
EP15803484.3A EP3153511B1 (en) 2014-06-06 2015-06-05 2-acylaminothiazole derivative for use in the prevention or treatment of bladder/urinary tract diseases

Publications (1)

Publication Number Publication Date
PL3153511T3 true PL3153511T3 (pl) 2019-09-30

Family

ID=54766887

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15803484T PL3153511T3 (pl) 2014-06-06 2015-06-05 Pochodna 2-acyloaminotiazolu do stosowania do profilaktyki lub leczenia chorób pęcherza moczowego/dróg moczowych

Country Status (34)

Country Link
US (2) USRE49111E1 (pl)
EP (1) EP3153511B1 (pl)
JP (1) JP6319436B2 (pl)
KR (1) KR102482844B1 (pl)
CN (2) CN110845490B (pl)
AR (1) AR100748A1 (pl)
AU (1) AU2015269449B2 (pl)
BR (1) BR112016028270B1 (pl)
CA (1) CA2950564C (pl)
CO (1) CO2017000044A2 (pl)
CY (1) CY1122290T1 (pl)
DK (1) DK3153511T3 (pl)
EA (1) EA031866B1 (pl)
ES (1) ES2732066T3 (pl)
HR (1) HRP20190943T1 (pl)
HU (1) HUE043496T2 (pl)
IL (1) IL249356B (pl)
LT (1) LT3153511T (pl)
MA (1) MA39950B1 (pl)
ME (1) ME03438B (pl)
MX (1) MX370140B (pl)
MY (1) MY197712A (pl)
NZ (1) NZ727142A (pl)
PH (1) PH12016502405B1 (pl)
PL (1) PL3153511T3 (pl)
PT (1) PT3153511T (pl)
RS (1) RS58809B1 (pl)
SA (1) SA516380427B1 (pl)
SG (2) SG10202000463YA (pl)
SI (1) SI3153511T1 (pl)
TR (1) TR201908676T4 (pl)
TW (2) TWI745877B (pl)
UA (1) UA122208C2 (pl)
WO (1) WO2015186821A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563915B (zh) 2006-12-20 2012-09-19 Gvbb控股股份有限公司 嵌入音频路由切换器
CN106573928B (zh) 2014-08-26 2020-04-14 安斯泰来制药株式会社 2-氨基噻唑衍生物或其盐
CA3044366A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
JPWO2019189766A1 (ja) * 2018-03-30 2021-04-08 持田製薬株式会社 新規ビアリールアミド誘導体
CN111718293A (zh) * 2019-03-18 2020-09-29 持田制药株式会社 双芳基酰胺衍生物的制造方法
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
WO2024122076A1 (ja) * 2022-12-09 2024-06-13 株式会社旭飛薬業 体液調節剤、体液調節用組み合わせ剤及び化合物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP2001278872A (ja) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
KR100544000B1 (ko) * 2000-05-25 2006-01-20 에프. 호프만-라 로슈 아게 치환된 1-아미노알킬-락탐 및 무스카린성 수용체길항제로서의 용도
JPWO2003037862A1 (ja) * 2001-10-30 2005-02-17 日本新薬株式会社 アミド誘導体及び医薬
ES2610611T3 (es) 2002-01-18 2017-04-28 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
TWI242478B (en) 2002-08-01 2005-11-01 Masami Nakamoto Metal nanoparticle and process for producing the same
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
US7361658B2 (en) 2003-07-17 2008-04-22 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
SG186850A1 (en) 2010-07-29 2013-02-28 Rigel Pharmaceuticals Inc Ampk-activating heterocyclic compounds and methods for using the same
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽

Also Published As

Publication number Publication date
SG10202000463YA (en) 2020-02-27
IL249356A0 (en) 2017-02-28
AR100748A1 (es) 2016-10-26
CO2017000044A2 (es) 2017-03-31
CN106414438B (zh) 2019-12-31
US20170197955A1 (en) 2017-07-13
PT3153511T (pt) 2019-06-28
JPWO2015186821A1 (ja) 2017-04-20
EA031866B1 (ru) 2019-03-29
BR112016028270B1 (pt) 2023-05-02
EP3153511B1 (en) 2019-05-15
SG11201610201UA (en) 2017-01-27
PH12016502405A1 (en) 2017-02-20
HRP20190943T1 (hr) 2019-09-20
WO2015186821A1 (ja) 2015-12-10
CN110845490A (zh) 2020-02-28
TR201908676T4 (tr) 2019-07-22
EP3153511A1 (en) 2017-04-12
HUE043496T2 (hu) 2019-08-28
MY197712A (en) 2023-07-09
MX370140B (es) 2019-12-03
DK3153511T3 (da) 2019-06-24
MA39950B1 (fr) 2019-08-30
TWI745877B (zh) 2021-11-11
CN110845490B (zh) 2023-03-28
EP3153511A4 (en) 2017-12-06
NZ727142A (en) 2022-10-28
RS58809B1 (sr) 2019-07-31
SI3153511T1 (sl) 2019-08-30
KR20170013987A (ko) 2017-02-07
CA2950564C (en) 2023-03-07
TW201613914A (en) 2016-04-16
USRE49111E1 (en) 2022-06-21
KR102482844B1 (ko) 2022-12-30
ES2732066T3 (es) 2019-11-20
EA201692469A1 (ru) 2017-05-31
IL249356B (en) 2019-11-28
JP6319436B2 (ja) 2018-05-09
TW202026294A (zh) 2020-07-16
LT3153511T (lt) 2019-07-10
ME03438B (me) 2020-01-20
CA2950564A1 (en) 2015-12-10
BR112016028270A2 (pt) 2022-07-19
US9951060B2 (en) 2018-04-24
TWI689507B (zh) 2020-04-01
MA39950A (fr) 2017-04-12
CY1122290T1 (el) 2021-01-27
CN106414438A (zh) 2017-02-15
MX2016016134A (es) 2017-03-08
AU2015269449B2 (en) 2019-03-14
PH12016502405B1 (en) 2017-02-20
UA122208C2 (uk) 2020-10-12
AU2015269449A1 (en) 2016-12-22
BR112016028270A8 (pt) 2023-01-17
SA516380427B1 (ar) 2019-11-28

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
HRP20180876T1 (hr) Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura
HUE062711T2 (hu) Ívelt vizelet katéter
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
RS58809B1 (sr) Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta
IL249458A0 (en) ppar compounds for use in the treatment of fibrotic diseases
IL250596A0 (en) The composition for the treatment and prevention of urinary tract infections
IL247969B (en) A medicinal component for use in the treatment of infections
PT3192512T (pt) Nova composição farmacêutica para prevenção e/ou tratamento de incontinência urinária
GB201420030D0 (en) Urinary catheter
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
GB201412972D0 (en) Flushable urinary catheter
SG10201405850PA (en) Composition for prevention or treatment of urinary tract infection
EP3242667C0 (en) FINAFLOXACIN FOR USE IN THE TREATMENT OF URINARY TRACT INFECTIONS
GB201614869D0 (en) Treatment of urinary tract disorders
AU2014902125A0 (en) A device for diagnosis and treatment of the urinary system